2020 Patient Melanoma & Skin Cancers
Collapse Spotlight on the Future of Treatment Algorithms in Melanoma: Where Are We Headed?

Access Course

 

Spotlight on the Future of Treatment Algorithms in Melanoma: Where Are We Headed?Experts discuss the use of checkpoint inhibition in metastatic melanoma as well as its expansion into the adjuvant setting and beyond.

 

This activity is intended for oncologists, dermatologists, and other healthcare professionals who treat patients with melanoma.

 

The goal of this activity is to increase understanding of the latest advances in the use of immunotherapy for the treatment of melanoma.

 

Learning Objectives:

  • Have increased knowledge regarding the emerging clinical trials data on the use of immune-modulating agents in the management of melanoma
  • Have increased knowledge regarding the place in therapy for immune checkpoint inhibitors in patients with melanoma

 

Approximate Time to Complete: 30 minutes

 

Credit Available: Mar. 4, 2020 - Mar. 4, 2021

 

Developed through a partnership between SITC and Medscape.

sitc_log_color.png     

Medscape_EDU-RGB-2x-300.png

 

Additional Melanoma Resources for Clinicans from SITC:

 

sitc-cig-rgb.png"The Society for Immunotherapy of Cancer consensus statement on tumor immunotherapy for the treatment of cutaneous melanoma" (Published May 30, 2018)

 

 

 

View Guidelines Here.

View On-demand Webinar Here.

Original Course Date: March 04, 2020

Approved Credit:
  • : 0.50 hours AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 Credit
  • ACCME (MD/DO): 0.50 hours AMA PRA Category 1 Credit(s)

  • MORE INFOMORE INFO Spotlight on the Future of Treatment Algorithms in Melanoma: Where Are We Headed?
    2019 Patient Melanoma & Skin Cancers